Keywords: P450 Antibody Antibodies Anti-Cytochrome THC
Title: Cytochrome P-450 isozymes in metabolic activation of delta 9-tetrahydrocannabinol by rat liver microsomes. ncbi.nlm.nih.gov/pubmed/1981541
ncbi.nlm.nih.gov/pubmed/23775837 Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure.
In this study, we found Abs present in sera of 15 of 19 cases of INH-induced liver failure. Anti-INH Abs were present in 8 sera; 11 had anti-cytochrome P450 (CYP)2E1 Abs, 14 had Abs against CYP2E1 modified by INH, 14 had anti-CYP3A4 antibodies, and 10 had anti-CYP2C9 Abs.
ncbi.nlm.nih.gov/pubmed/8987248 Anti-cytochrome P450 autoantibodies in drug-induced disease.
These drugs are transformed into reactive metabolite(s) by cytochrome P450 (2C9 for TA and 1A2 for DH) (step 1). The reactive metabolites produced are very short-lived and bind directly to the enzymes which generated them (step 2). A neoantigen is thus formed which triggers an immune response (step 3), characterized by the presence of autoantibodies in the patient’s serum (step 4). The autoantibodies are directed against the cytochrome P450 which generated the metabolite(s).
